Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
"Spontaneous But Not Experimental Metastatic Activities Differentiate Primary Tumor-Derived vs. Metastasis-Derived Mouse Prostate Cancer Cell Lines."
November 24th, 1997
According to the authors' abstract of an article published in Clinical & Experimental Metastasis, "We previously developed an in vivo mouse prostate reconstitution (MPR) model of metastatic prostate cancer using p53 'knockout' mouse urogenital sinus tissue for retroviral transduction of ras and myc oncogenes (Thompson et al., Oncogene, 10, 869, 1995). We further demonstrated contrasting responses to transforming growth factor beta-1 (TGF-beta 1) in three matched pairs of early passage cell lines derived front primary prostate tumors and lung metastases generated by this model system (Sehgal et al., Cancer Res, 56, 3359, 1996). In this study we tested these cell lines for growth potential...
Source: Cancer Weekly (1997-11-24)
|
|
Advertisement |
|
|
